Brivaracetam Renal Dosing
No dose adjustment of brivaracetam is required for patients with renal impairment at any stage, including severe renal dysfunction. 11
Dosing Recommendations by Renal Function
Standard dosing applies across all levels of renal impairment:
- Mild to moderate renal impairment (CrCl ≥30 mL/min): Use standard dosing without adjustment
- Severe renal impairment (CrCl <30 mL/min): Use standard dosing without adjustment
- End-stage renal disease: Standard dosing applies, though brivaracetam has not been studied in patients undergoing hemodialysis 11
The standard adult dosing range is 50-200 mg/day divided into twice-daily doses (25-100 mg twice daily).
Pharmacokinetic Rationale
The FDA drug label provides clear evidence that dose adjustment is unnecessary despite renal impairment 11. In patients with severe renal impairment (CrCl <30 mL/min), brivaracetam exposure (AUC) increases only modestly by 21% compared to healthy controls. This minimal increase does not warrant dose reduction.
Key pharmacokinetic findings:
- Less than 10% of brivaracetam is excreted unchanged in urine
- Primary elimination occurs through hepatic metabolism (hydrolysis and hydroxylation)
- The three metabolites (acid, hydroxy, and hydroxyacid) are pharmacologically inactive
- While metabolite levels increase substantially in renal impairment (3-21 fold), these metabolites lack pharmacologic activity and nonclinical toxicology studies showed no safety concerns 2
Clinical Evidence
A dedicated renal impairment study 2 confirmed that brivaracetam's pharmacokinetic profile remains acceptable in severe renal dysfunction. The study demonstrated:
- Cmax unchanged in severe renal impairment
- AUC increased by only 21% (90% CI: 1.01-1.45)
- No safety issues related to increased metabolite levels
Recent research 3 further confirms that brivaracetam's pharmacokinetic profile eliminates the need for dosage adjustment in renal impairment, supporting its use in pediatric populations as well.
Important Caveats
Hemodialysis patients: Brivaracetam has not been formally studied in patients requiring hemodialysis 11. Exercise clinical judgment and monitor closely if used in this population, though standard dosing is reasonable given the drug's minimal renal excretion.
Hepatic impairment requires dose reduction: Unlike renal impairment, hepatic dysfunction does necessitate dose adjustment (reduce to 50% of standard dose for all stages of hepatic impairment) 11.